Due to a more favourable environment, PACIFIC BSCS.OF CAL. slightly increases to Slightly Negative
PACIFIC BSCS.OF CAL. (US), a company active in the Biotechnology industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Slightly Negative even if it remains under pressure. As of the analysis date December 17, 2021, the closing price was USD 21.04 and its target price was estimated at USD 13.71.Pacific Biosciences of California designs, develops and manufactures sequencing systems. Based on its Single Molecule, Real-Time sequencing technology, the company's products enable: de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in gene families, and find genes; targeted sequencing to characterize genetic variations; and real-time kinetic information for epigenome characterization. The PacBio RS II, Sequel, and Sequel II Systems conduct, monitor, and analyze biochemical sequencing reactions.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.